Company / Operating Cash Flow
Marker Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$27.3M
FY2021
5-year range
-$27.3M / -$8.4M
FY2018-FY2021
Trend
-49.2%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$8M to -$27M over the past 3 years.
Based on SEC 10-K filings.
-$27M in FY2021.
Declined from -$8M to -$27M over the past 3 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, operating cash flow decreased 49.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | -$27.3M | -49.2% |
| FY2019 | -$18.3M | -116.7% |
| FY2018 | -$8.4M | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026